nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-E8693528·Framework v5.0·Pipeline v0.4·Evaluated 09 Jul 2026·OECD: 3.1 Basic medicine·Subfield: Molecular Biology·Basis: Full text·Type: Laboratory experiment

Circular RNA UBAP2 contributes to tumor growth and metastasis of cervical cancer via modulating miR-361-3p/SOX4 axis.

Meng et al.Meng, Jia, Yu et al.·2020·Cancer cell international·10.1186/s12935-020-01436-z ↗

In brief

A competent ceRNA mechanism study that nominates circUBAP2 in cervical cancer, constrained by preliminary models and reporting inconsistencies.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

BACKGROUND: Increasing researches have reported that circular RNA UBAP2 (circUBAP2) may be a potential prognosis biomarker and participate in the development of several cancers; however, the role of circUBAP2 in cervical cancer (CC) remains largely unclear.

METHODS: We applied qRT-PCR and Western blot to examine expression levels of circUBAP2, miR-361-3p, SOX4, Bax, Bcl-2, Cleaved caspase 3, N-cadherin, Vimentin and E-cadherin. Cell proliferation, apoptosis, invasion and migration were analyzed by MTT assay, Flow cytometry, and Transwell assay, respectively. The interaction between miR-361-3p and circUBAP2 or SOX4 was confirmed by luciferase reporter assay and pull-down assay. Murine xenograft model was established by injecting SiHa cells which stably transfected sh-circUBAP2.

RESULTS: CircUBAP2 was up-regulated in CC tissues and cell lines and high circUBAP2 expression predicated poor outcome. Knockdown of circUBAP2 suppressed cell proliferation, migration, invasion and EMT, while induced apoptosis in CC in vitro, and inhibited tumor growth and metastasis in vivo. MiR-361-3p directly bound to circUBAP2 or SOX4, and circUBAP2 could regulate SOX4 expression by sponging miR-361-3p in CC cells. Furthermore, rescue assay results demonstrated that the inhibitory effects of circUBAP2 knockdown on cell growth and metastasis were partially reversed by miR-361-3p down-regulation or SOX4 up-regulation in CC.

CONCLUSION: CircUBAP2 represents a prognostic marker and contributes to tumor growth and metastasis via modulating miR-361-3p/SOX4 axis in CC, which indicates a potential therapeutic target for CC treatment.

Strengths · Limitations

Strengths

#methodological rigour

Layered evidence for proposed mechanism

The paper connects expression profiling, RNase R resistance, cytoplasmic localization, luciferase reporter assays, pull-down assays, and rescue experiments into a coherent circUBAP2/miR-361-3p/SOX4 mechanism. This provides more support than a descriptive expression-only study.

↳ Results Figs. 1, 3, 4, and 5

#methodological rigour

Functional rescue supports axis specificity

The rescue experiments test whether miR-361-3p inhibition or SOX4 overexpression reverses the effects of circUBAP2 knockdown on proliferation, apoptosis, migration, invasion, and EMT markers. This directly supports the proposed mechanistic chain in vitro.

↳ Results, CircUBAP2 deletion inhibits the CC cell progression in vitro via serving as a ceRNA; Fig. 5

#contribution

In vivo experiments extend cell findings

The study goes beyond cell culture by testing sh-circUBAP2-transfected SiHa cells in subcutaneous tumor growth and tail-vein lung nodule models. These experiments provide preliminary in vivo support for growth and metastasis-related phenotypes.

↳ Methods, Xenograft Experiments in Vivo; Results Fig. 6

Limitations

#methodological rigour

Animal numbers are internally inconsistent

The Methods describe N=10 total mice, with 6 used for subcutaneous injection and another 4 for tail-vein metastasis, while the Results describe two groups of 5 mice for the tail-vein experiment. This weakens confidence in the in vivo metastasis reporting.

↳ Methods, Xenograft Experiments in Vivo; Results, CircUBAP2 promotes CC cell growth and metastasis in vivo

#application pathway

Clinical claims exceed survival reporting

The manuscript states that high circUBAP2 predicts poor outcome and frames circUBAP2 as a prognostic marker, but the survival analysis is based on 58 paired tissues and does not report group definition or covariate adjustment. The therapeutic-target framing is also based on genetic knockdown in preclinical models rather than a deployable intervention.

↳ Results Fig. 1c; Abstract; Conclusion

#positioning

Model diversity limits generalizability

Functional work is performed in HeLa and SiHa cells, while C-33A is included in expression characterization but not in functional assays. This leaves HPV-negative or broader cervical-cancer contexts insufficiently tested.

↳ Methods, Cell Culture; Results Figs. 1–6

Does this match your read? Add your assessment ↓

Nabu Commentary

The adjudicated quality score reflects a competent but conventional mechanistic cancer-biology paper. The strongest article-level support comes from the layered assays in Figs. 1–5 and the in vivo extension in Fig. 6, which together support the proposed circUBAP2/miR-361-3p/SOX4 axis as a preclinical mechanism. The score is held below the stronger range because the in vivo metastasis experiment has conflicting sample-size descriptions, the survival claim is underreported, and the functional models are narrow. Impact potential is lower than quality because the paper does not define a clinical use case, validate a biomarker assay, or test a therapeutic delivery approach.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.2

Contribution
2.9

The study adds a specific circUBAP2/miR-361-3p/SOX4 axis to cervical-cancer biology and supports it with expression, binding, rescue, and mouse experiments. The contribution remains incremental because it applies a familiar circRNA-ceRNA template to a new disease context and makes prognostic or therapeutic claims from preliminary evidence.

Background; Results Figs. 1–6; Conclusion

the role of circUBAP2 in CC is still largely unclear

Methodological Rigour
2.9

The experimental sequence is broadly fitted to the mechanistic claim, combining qRT-PCR, RNase R treatment, localization, luciferase and pull-down assays, rescue experiments, and xenograft work. Methodological Rigour is limited by inconsistent animal sample-size reporting, underreported survival analysis, limited functional cell-line diversity, and no in vivo mechanistic rescue.

Methods, Cells Transfection and Xenograft Experiments in Vivo; Results Figs. 1–6

another two groups of 5 mice

Reporting
3.2

The results are organized in a conventional and traceable progression from expression to function, mechanism, rescue, and in vivo testing. Reporting is reduced by repeated wording errors, shRNA/siRNA terminology drift, and an apparent Fig. 5f/Fig. 6f cross-reference error in the in vivo section.

Results sections for Figs. 1–6; Results, CircUBAP2 promotes CC cell growth and metastasis in vivo

as depicted in microphotographs and histograms in Fig. 5f

Positioning
2.8

The paper gives adequate background on circRNAs, circUBAP2 in other cancers, miR-361-3p, and SOX4 in cervical cancer. Its contextual framing is mostly confirmatory and does not critically address ceRNA stoichiometry, HPV-related heterogeneity, xenograft limitations, or the limited basis for prognostic claims.

Background; Discussion; Discussion, limitations paragraph

a larger cohort of the disease analysis is essential

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The main mechanistic narrative is coherent, but reporting inconsistencies and overextended prognostic or therapeutic language reduce confidence in precision. The most material issue is inconsistent mouse-number reporting for the in vivo metastasis experiment.

Research ConductNoted

Human and animal ethics approval and informed consent are declared, but approval identifiers are not provided and open-science transparency is minimal. No data availability, code availability, or reporting-standard declaration is evident in the supplied text.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 35 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Cervical cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 1.6
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The circUBAP2/miR-361-3p/SOX4 mechanism was pinned down in cell lines and mouse xenograft models under controlled conditions, with no human validation beyond a small tissue-expression cohort.

From the paper
“which indicates a potential therapeutic target for CC treatment”

The paper names a possible real-world use of its findings as a therapeutic target and prognostic marker for cervical cancer, but does not specify who would act on them or in what setting.

Pathway

Drug developers and oncology researchers could design inhibitors of circUBAP2 or modulators of the miR-361-3p/SOX4 axis as targeted therapies for cervical cancer patients.

Barrier

The findings rest on cell lines, a small tissue cohort and mouse xenografts, so demonstrating safe delivery and efficacy in cervical cancer patients remains unproven.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression

    Min-Cheng Yu, Guang-Yu Ding, Peng Ma, et al. · 2021 · Clinical medicine

    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  2. Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496

    Fu, Liu, Zhao, et al. · 2023 · Clinical medicine

    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. CircUBAP2 Promotes MMP9-Mediated Oncogenic Effect via Sponging miR-194-3p in Hepatocellular Carcinoma

    Liu, Tian, Chen, et al. · 2021 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    Caveats

How the rubric works →